» Articles » PMID: 20880390

Long-lasting Target Binding and Rebinding As Mechanisms to Prolong in Vivo Drug Action

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2010 Oct 1
PMID 20880390
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

An increasing number of examples in the literature suggest that the in vivo duration of drug action not only depends on macroscopic pharmacokinetic properties like plasma half-life and the time needed to equilibrate between the plasma and the effect compartments, but is also influenced by long-lasting target binding and rebinding. The present review combines information from different research areas and simulations to explore the nature of these mechanisms and the conditions in which they are most prevalent. Simulations reveal that these latter phenomena become especially influential when there is no longer sufficient free drug around to maintain high levels of receptor occupancy. There is not always a direct link between slow dissociation and long-lasting in vivo target protection, as the rate of free drug elimination from the effect compartment is also a key influencing factor. Local phenomena that hinder the diffusion of free drug molecules away from their target may allow them to consecutively bind to the same target and/or targets nearby (denoted as 'rebinding') even when their concentration in the bulk phase has already dropped to insignificant levels. The micro-anatomic properties of many effect compartments are likely to intensify this phenomenon. By mimicking the complexity of tissues, intact cells offer the opportunity to investigate both mechanisms under the same, physiologically relevant conditions.

Citing Articles

IGF2BP1 phosphorylation in the disordered linkers regulates ribonucleoprotein condensate formation and RNA metabolism.

Hornegger H, Anisimova A, Muratovic A, Bourgeois B, Spinetti E, Niedermoser I Nat Commun. 2024; 15(1):9054.

PMID: 39426983 PMC: 11490574. DOI: 10.1038/s41467-024-53400-4.


Exploring the potential of in Alzheimer's disease treatment: An approach.

Irsal R, Gholam G, Dwicesaria M, Mansyah T, Chairunisa F J Taibah Univ Med Sci. 2024; 19(5):947-960.

PMID: 39397872 PMC: 11470288. DOI: 10.1016/j.jtumed.2024.09.003.


Bispecific FpFs: a versatile tool for preclinical antibody development.

Collins M, Ibeanu N, Grabowska W, Awwad S, Khaw P, Brocchini S RSC Chem Biol. 2024; .

PMID: 39347456 PMC: 11427889. DOI: 10.1039/d4cb00130c.


Simplified Method for Kinetic and Thermodynamic Screening of Cardiotonic Steroids through the K-Dependent Phosphatase Activity of Na/K-ATPase with Chromogenic pNPP Substrate.

Azalim-Neto P, Noel F, Silva S, Villar J, Barbosa L, ODoherty G Mol Pharmacol. 2024; 106(5):225-239.

PMID: 39187390 PMC: 11493336. DOI: 10.1124/molpharm.124.000934.


Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition.

Kenakin T Nat Rev Drug Discov. 2024; 23(8):626-644.

PMID: 38890494 DOI: 10.1038/s41573-024-00958-9.


References
1.
Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K . Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol. 1997; 319(1):137-46. DOI: 10.1016/s0014-2999(96)00837-0. View

2.
Bader R, Bettio A, Beck-Sickinger A, Zerbe O . Structure and dynamics of micelle-bound neuropeptide Y: comparison with unligated NPY and implications for receptor selection. J Mol Biol. 2000; 305(2):307-29. DOI: 10.1006/jmbi.2000.4264. View

3.
Berry H . Monte carlo simulations of enzyme reactions in two dimensions: fractal kinetics and spatial segregation. Biophys J. 2002; 83(4):1891-901. PMC: 1302281. DOI: 10.1016/S0006-3495(02)73953-2. View

4.
Fierens F, Vanderheyden P, De Backer J, Vauquelin G . Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol. 1999; 367(2-3):413-22. DOI: 10.1016/s0014-2999(98)00965-0. View

5.
Van Liefde I, Vauquelin G . Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2008; 302(2):237-43. DOI: 10.1016/j.mce.2008.06.006. View